Faculty Profile: Lawrence H. Price, MD

Lawrence H. Price
Lawrence H. Price, MD
Professor of Psychiatry & Human Behavior
Psychiatry & Human Behavior
Work: +1 401-455-6533
Dr. Price is currently engaged in studies focused on mood disorders, including the neuroendocrine and neurochemical sequelae of stress and early life experience as risk factors for major affective illness and the development of novel pharmacological and electrophysiological monotherapy and combination treatment approaches to mood and anxiety disorders.

Biography

Dr. Price attended the University of Michigan, where he first received a B.S. with highest honors in psychology and high distinction in 1974, followed by an M.D. in 1978. After an internship in internal medicine at Norwalk Hospital, he completed a residency and fellowship in psychiatry at Yale University. From 1982 until 1996, Dr. Price was on the faculty in the Department of Psychiatry at Yale University, where he served as Associate Professor and Director of the Clinical Neuroscience Research Unit at the Connecticut Mental Health Center. Since 1996, he has served as Professor of Psychiatry at Brown University and Clinical Director and Director of Research at Butler Hospital in Providence, Rhode Island, as well as Chair of the Butler Hospital Institutional Review Board. In addition to his research activities, Dr. Price has received numerous awards for his teaching and clinical work, and is Editor of the Brown University Psychopharmacology Update.

Institutions

Bh

Research Description

Lawrence Price's primary research interests have involved the phenomenology, clinical psychopharmacology, neuropharmacology, and neurobiology of mood, anxiety, and substance abuse disorders. He has published extensively on pharmacologic approaches to the treatment of refractory and psychotic depression. In this regard, he conducted many of the early studies on the use of lithium augmentation, subsequently extending this work during investigations of fenfluramine, yohimbine, and neuroleptics as augmenting agents. His more recent studies in this area have addressed the efficacy of maintenance ECT, glucocorticoid antagonists, and atypical antidepressant combination approaches. He completed a large series of investigations concerning the effects of antidepressant drugs on serotonin function in humans and was involved in pioneering studies demonstrating the relationship between intact serotonin function and antidepressant efficacy in depressed patients using the tryptophan depletion paradigm. He is currently engaged in studies focused on mood disorders, including the neuroendocrine and neurochemical sequelae of stress and early life experience as risk factors for major affective illness, the use of deep brain stimulation and other electrophysiological modalities in the treatment of intractable depression, and the development of novel pharmacological monotherapy and combination treatment approaches to mood and anxiety disorders.

He was one of the principal developers of the Yale-Brown Obsessive Compulsive Scale (Y-BOCS), now considered the standard instrument for assessing treatment response in obsessive-compulsive disorder (OCD). He was a lead investigator in the first controlled trial of a selective serotonin reuptake inhibitor (SSRI) for the treatment of OCD in the U.S. and conducted numerous other studies on this condition concerning symptom assessment, genetics, cerebrospinal fluid metabolite levels, neurochemical function, and novel pharmacologic treatment approaches. He was involved in the first controlled studies to examine the efficacy of combining conventional and atypical neuroleptics with SSRIs for the treatment of refractory OCD, as well as the first controlled studies of SSRIs and atypical neuroleptics in the treatment of autism. He was also active in investigating the clinical neurobiology of cocaine-induced euphoria and cocaine abstinence in humans. He has published over 390 scientific papers, and was identified by the Institute for Scientific Information as one of the top ten authors of high-impact papers in psychiatry from 1990 to 1999.

He attended the University of Michigan, where he first received a B.S. with highest honors in psychology and high distinction in 1974, followed by an M.D. in 1978. After an internship in internal medicine at Norwalk Hospital, he completed a residency and fellowship in psychiatry at Yale University. From 1982 until 1996, Dr. Price was on the faculty in the Department of Psychiatry at Yale University, where he served as Associate Professor and Director of the Clinical Neuroscience Research Unit at the Connecticut Mental Health Center. Since 1996, he has served as Professor of Psychiatry at Brown University and Clinical Director and Director of Research at Butler Hospital in Providence, Rhode Island, as well as Chair of the Butler Hospital Institutional Review Board. In addition to his research activities, Dr. Price has received numerous awards for his teaching and clinical work, and is Editor of the Brown University Psychopharmacology Update and Principal Editor for clinical psychopharmacology of Psychopharmacology.

Grants and Awards

National Merit Scholar, 1970-1974.
Honors Program in Psychology, Univ. of Michigan, 1970-1974.
Phi Eta Sigma National Freshman Honor Society (invitation), 1971.
William J. Branstrom Prize (for "outstanding freshman performance"), Univ. of Michigan, 1971.
B.S. with High Distinction and Highest Honors in Psychology, Univ. of Michigan, 1974.
Phi Beta Kappa, Univ. of Michigan, 1974.
Outstanding Intern Award, Norwalk Hosp. (in affiliation with Yale Univ. Schl. of Medicine), 1979.
Laughlin Fellow (for "most promising resident"), American College of Psychiatry, 1981.
Laughlin Award for Merit (for "professional achievement, dedication, and scholarship"), National Psychiatric Endowment Fund, 1982.
Stephen Fleck Faculty Award (for "exemplary physician and clinical teacher"), Department of Psychiatry, Yale Univ. Schl. of Medicine, 1985.
Sigma Xi Scientific Research Society, Yale Univ., 1988.
Award for Excellence in Teaching, Yale Psychiatry Residents Association, Yale Univ. Schl. of Medicine, 1991.
Citation, Best Doctors, Best Doctors, Inc., Aiken, SC, 1994-2010.
Outstanding Teaching Award in Medical School Education, Department of Psychiatry and Human Behavior, Brown Univ. Schl. of Medicine, 1997.
Master of Arts ad eundem, Brown Univ., 1998.
Outstanding Teaching Award in General Psychiatry, Department of Psychiatry and Human Behavior, Brown Univ. Schl. of Medicine, 1999.
Research Mentor Award, Department of Psychiatry and Human Behavior, Brown Univ. Schl. of Medicine, 2000, 2006.
Citation, top 10 authors of high-impact papers in psychiatry, 1990-1999, Institute for Scientific Information, Philadelphia, 2000.
Dean's Teaching Excellence Award (for "exemplary teaching in Bio 510: Clerkship in Psychiatry"), Brown Medical School, 2001.
Faculty Development Mentorship Award in Psychopharmacology, Janssen Pharmaceutica Psychiatry Distinguished Awards Program, 2003.
Citation, America's Top Doctors, Castle Connolly Medical Ltd, NY, NY, 2003-2010.
Distinguished Fellow, American Psychiatric Association, 2004.
Citation, Highly Cited Researcher in psychology/psychiatry, 1981-1999, Thomson ISI, Philadelphia, http://isihighlycited.com/, 2004.
Faculty Mentoring Award, Department of Psychiatry and Human Behavior, Brown Univ. Schl. of Medicine, 2005.
APEX 18th Annual Award for Publication Excellence, "Newsletter Writing - Brown University Psychopharmacology Update," Communications Concepts, Inc, Springfield, VA, 2006.
Citation, top 4 psychiatrists for men, Northeast, Men's Health, April, 2007.
Citation, top 4 psychiatrists for women, Northeast, Women's Health, November, 2008.
Fellow, American College of Neuropsychopharmacology, 2011.

Affiliations

ACADEMIC APPOINTMENTS

Assistant Professor of Psychiatry, Yale University School of Medicine, New Haven, CT, 1983-1989.
Associate Unit Chief, Clinical Neuroscience Research Unit, Connecticut Mental Health Center, New Haven, CT, 1983-1988.
Co-Chief, Depression Clinic, Clinical Neuroscience Research Unit, Connecticut Mental Health Center, New Haven, CT, 1984-1987.
Chief, Inpatient Division, Clinical Neuroscience Research Unit, Connecticut Mental Health Center, New Haven, CT, 1984-1996.
Director, Clinical Neuroscience Research Unit, Connecticut Mental Health Center, New Haven, CT, 1988-1996.
Chief, Depression Clinic, Clinical Neuroscience Research Unit, Connecticut Mental Health Center, New Haven, CT, 1988-1995.
Associate Professor of Psychiatry, Yale University School of Medicine, New Haven, CT, 1989-1996.
Professor of Psychiatry and Human Behavior, Brown University School of Medicine, Providence, RI, 1996-.
Director of Research, Butler Hospital, Providence, RI, 1996-.
Chief, Mood Disorders Program, Butler Hospital, Providence, RI, 1996-1997.
Medical Director, Butler Hospital, Providence, RI, 1997-8.
Clinical Director, Butler Hospital, Providence, RI, 1998-.
Interim Chief, General Adult Treatment Unit, Butler Hosp., Providence, RI, 2007.
Graduate Medical Education Designated Institutional Official, Butler Hosp., Providence, RI, 2009-.



HOSPITAL APPOINTMENTS

Attending psychiatrist, Yale-New Haven Hospital, New Haven, CT, 1982-83; 1988-1996.
Attending psychiatrist, Connecticut Mental Health Center, New Haven, CT, 1983-1996.
Attending psychiatrist, Butler Hospital, Providence, RI, 1996-.
Attending psychiatrist, Kent Hospital, Warwick, RI, 1997-.

Funded Research

GRANTS

1. University of Michigan Student Medical Research Grant, "Computer simulation of motivation and action," Princ. Investig.; 6/75-8/75, $900.
2. NIMH P50 MH30929, "Clinical Science Research Center in Psychiatry," Co-investig.; 9/77-8/97, $3,425,686 [most recent funding cycle].
3. NIMH P01 MH25642, "Neurobiologic basis of major psychiatric disorders," Co-investig.;7/78-6/96, $3,458,203 [most recent funding cycle].
4. NIMH R01 MH36229, "Monoamine receptor sensitivity and antidepressant drugs," Co-investig.; 4/82-8/92, $357,469 [most recent funding cycle].
5. NIDA P05 DA04060, "Clinical Research Center for Opioid and Cocaine Use" (Component: "Clinical neurobiology of cocaine withdrawal and administration"), Component Princ. Investig.; 8/86-7/96, $619,142 [most recent funding cycle].
6. CIBA-GEIGY Pharmaceuticals, "Anafranil vs. placebo in the treatment of OCD - Extension Phase," Princ. Investig.; 6/87-1/89, $36,500.
7. NIMH K08 MH00579 (Clinical Investigator Award), "Neurobiology and treatment of refractory depression," Princ. Investig.; 8/87-7/90, $160,474.
8. Pfizer Pharmaceuticals, "Double-blind comparison of SM-3997 and placebo in outpatients with depression," Princ. Investig.; 5/88-6/90, $60,600.
9. NIDA R18 DA06190, "Treatment Research Unit: Reducing AIDS risk by pharmaco- and psychotherapy," Co-investig.; 8/89-9/94, $2,685,673.
10. NIMH R01 MH47894, "Rapid treatment of major depression, " Co-investig.; 5/92-4/95, $461,143.
11. Parke-Davis, "A single-blind, placebo-controlled crossover study of oral CI-988 for anxiety in patients with GAD," Princ. Investig.; 5/92-6/93, $36,980.
12. Miles Pharmaceuticals, "A multicenter, double-blind, placebo-controlled, parallel-group study of the safety, tolerability, and efficacy of three fixed doses of ipsapirone CR (Bay Q7821) vs placebo in outpatients with moderate to severe major depressive disorder (MDD)," Princ. Investig.; 8/93-8/94, $124,800.
13. Stanley Foundation Research Awards Program, National Alliance for the Mentally Ill, "The role of monoaminergic function in the mechanism of action of lithium in mania," Princ. Investig.; 8/94-8/96, $128,000.
14. NIDA R01 DA09330-01, "Serotonin/dopamine antagonism of cocaine effect," Princ. Investig.; 9/94-8/97, $673,686; extended to 8/98, with administrative increase of $55,532.
15. Solvay Pharmaceuticals, Unrestricted grant, Princ. Investig.; 5/95, $50,000.
16. Departmental Research Award, Brown Univ. Dept. of Psychiatry and Human Behavior, "The genetics of dopamine -hydroxylase in psychotic and nonpsychotic depression," Princ. Investig.; 7/97 - 6/98, $15,888.
17. Solvay Pharmaceuticals, "A multicenter, double-blind, placebo-controlled, parallel group study of the safety, tolerability and efficacy of three fixed doses of fluvoxamine vs placebo in outpatients with major depressive disorder," Princ. Investig.; 9/97 - 8/98, $242,120.
18. Pfizer, Inc., "A phase III, randomized, placebo-controlled study evaluating the safey and outcome of treatment with oral ziprasidone in subjects with mania receiving lithium," Princ. Investig.; 1/98 - 1/99, $169,313.
19. Pfizer, Inc., "An open extension study evaluating the safety and outcome of 40-160 mg daily of oral ziprasidone in the treatment of subjects who have participated in Protocol 602," Princ. Investig.; 1/98 - 1/00, $36,300.
20. Forest Laboratories, Inc., "An open-label evaluation of the efficacy, safety, and dosing of citalopram in outpatients with depression," Princ. Investig.; 2/98 - 3/99, $40,040.
21. Forest Laboratories, Inc.,"An open-label extension of citalopram treatment in outpatients with depression," Princ. Investig; 3/98- 3/99, $29,912.
22. Eli Lilly and Co., "Comparative efficacy of switching SSRI nonresponders to fluoxetine vs continued antidepressant treatment with the same SSRI," Princ. Investig.; 3/98 - 3/00, $74,961.
23. Pfizer, Inc., "Validation of serial CSF collection method for assessment of central serotonergic function," Princ. Investig.; 7/98 - 10/98, $47,956.
24. Merck Research Laboratories, "A double-blind, multicenter study of two doses of L-759274 vs paroxetine hydrochloride and placebo in the treatment of outpatients with major depressive disorder," Investigator; 8/99 - 3/00, $197,520.
25. Pfizer, Inc., "A six-week, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of 3 doses of CP-448,187 (0.5, 3, and 10 mg) and fluoxetine (Prozac) in subjects with major depressive disorder," Princ. Investig.; 5/00- 5/02, $82,797.
26. NIMH RO1 MH58866-01, "Combined treatment for depressed inpatients," Co-Princ. Investig.; 6/00 – 7/05, $2,352,122.
27. NCI R21 CA88297-01, "Behavioral vulnerability to early smoking relapse," Co-Investig.; 7/00 – 6/02, $362,500.
28. Cyberonics, "A multicenter, pivotal, safety and efficacy study of the NeuroCybernetic Prosthesis (NCP) system in patients with depression," Co-Investig., 2/00-2/02, $117,145.
29. Cyberonics, "A long-term, prospective, multicenter study to compare the clinical, quality of life, and health care utilization outcomes of the NeuroCyberonic Prosthesis (NCP) System to the standard of care treatment in patients with depression," Co-Investig., 1/01-1/03, $61,680.
30. Cyberonics, "CSF neurochemical correlates of vagus nerve stimulation in depressed patients," Co-Investig., 1/01-1/03, $108,725.
31. Thuris Corp., "Evoked response potentials in mood disorders. I.," Princ. Investig.; 6/01-6/02, $10,000.
32. Scirex Corp./Corcept Therapeutics, Inc., "1073-02: A phase III, randomized, double-blind, placebo-controlled study of the safety and efficacy of C-1073 (mifepristone) in patients with major depressive disorder with psychotic features," Co-Investig., 11/01-11/02, $14,967.
33. Scirex Corp./Corcept Therapeutics, Inc., "1073-02: A phase III, randomized, double-blind, placebo-controlled study of the safety and efficacy of C-1073 (mifepristone) in patients with major depressive disorder with psychotic features who are not receiving antidepressants or antipsychotics," Co-Investig., 11/01-11/02, $14,967
34. Merck Research Laboratories, "A worldwide, multicenter, double-blind, parallel, active-controlled, long-term safety study of MK-0869 in outpatients with major depressive disorder (Protocol 066-00)," Princ. Investig.; 2/02-2/03, $251,880.
35. Cephalon, Inc. "An open-label, 8-week study with flexible doses of Gabitril™ (tiagabine hydrochloride) in patients with major depressive disorder with anxiety (MDD-A)," Co-Investig., 3/02-3/03, $127,500.
36. Thuris Corp., "Evoked response potentials in mood disorders. II.," Princ. Investig.; 7/02-8/03, $45,555.
37. American Cancer Society RSGPB PBP-103382, "Improving smoking cessation in smokers with depressive symptoms," Co-Investig., 7/02-6/06, $1,264,374.
38. Medtronic, Inc., "Electrical Stimulation of the Anterior Limb of the Internal Capsule to Treat Major Depressive Disorder," Co-Investig., 10/02-9/04, $315,000.
39. Pfizer, Inc., "Sertraline treatment and cortisol response to the DEX/CRH test in healthy subjects," Co-Investig., 12/03-12/06, $125,260.
40. NIMH RO1 MH068767-01, "DEX/CRH response: Mood/anxiety disorder endophenotype?," Co-Investig.; 4/04–3/08, $1,227,776.
41. NCCAM/NIMH RO1 AT001742-01, "Double-blind, placebo-controlled study of SAMe vs. escitalopram in MDD," Princ. Investig.; 4/04-3/09, $1,087,938.
42. US Dept of Defense, "Perceived early life stress and DEX/CRH test response as predictors of psychological sequelae following exposure of healthy adults to war stress," Co-Investig.; 7/04–6/05, $40,000.
43. UCB Pharma, Inc., "Keppra treatment and cortisol response to the DEX/CRH test in healthy subjects," Co-Investig.; 6/04–12/06, $111,624.
44. Sepracor, Inc. ESRC101, "Eszopiclone treatment and cortisol response to HPA Axis tests," Co-Investig; 9/06–6/08, $254,319.
45. Cyberonics, Inc., "Randomized comparison of outcomes in patients with treatment-resistant depression who receive VNS therapy administered at different amounts of electrical charge," Co-Investig., 11/07-9/10; $286,350.
46. NIDA RO1 DA023190-01A1, "Sequential use of fluoxetine for smokers with elevated depressive symptoms," Co-Investig.; 9/07–3/12, $2,374,108.
47. Medtronic, Inc., "RECLAIM deep brain stimulation (DBS) clinical study for treatment-resistant depression," Co-Investig., 4/09-6/11.
48. Neuronetics, Inc., "NeuroStar Transcranial Magnetic Stimulation Therapy® System: Data management, analysis and reporting format for clinical treatment utilization and outcomes," Co-Investig., 9/09–9/10.
49. HRSA C76HF19883, "Health care and other facilities (Butler Hospital's Center for Advanced Diagnostics and Therapeutics In Alzheimer's Disease)," Progr. Dir.; 9/10-9/11, $198,000.
50. NIMH R21 MH091508, "Childhood Maltreatment: Epigenetic Modulation of the Glucocorticoid Receptor," Co-Investig., 4/11-3/13; $388,694.
51. NeoSync, Inc. "Evaluation of Low Emission NeoSync EEG Synchronized TMS Technology for the Treatment of Major Depressive Disorder: A Multicenter Randomized, Double-Blind, Sham-Controlled, Trial," Co-Investig., 4/11-4/14.

Teaching Experience

Brown University

Supervisor/preceptor, 3rd- and 4th-year Brown medical student clerks, 1996-.
Supervisor, Brown psychiatry residents and fellows (PGY-1 - PGY-6), 1996-.
Doctor-on-call supervisor, Butler Hosp. Patient Assessment Service, 1996-.
Lecturer, PGY-2 Seminar Series, 1996-2002.
Visiting faculty (examiner), Dartmouth Dept. of Psychiatry Mock Board Examination, 1996.
Lecturer, PGY-3 Neuropsychiatry Seminar, 1997-2002.
Lecturer, PGY-4 Seminar Series, 1997-2002.
Residency Track Coordinator, Research, 1997-2000.
Director, Clinical Case Conference Series, Butler Hosp., 1997-.
Lecturer, "Neural regulation of affect and mood" (in "Biomed 370: The Human Brain and Behavior", for 1st-year Brown medical students), 1998-2004.
Faculty, Combined Treatment T32 Postdoctoral Fellowship Core Seminar Series, 1998-2002, 2010.
Faculty advisor, undergraduate honors thesis (Dept. of Neuroscience), 2001-2002.
Invited faculty, Residents Journal Club, 2002-2010.
Leader, "PGY-4 Advanced Topics in Psychiatry Seminar", 2003-.
Faculty, PGY-1,2 Psychopharmacology Seminar Series, 2003-.
Faculty, PGY-3 Psychopharmacology Seminar Series, 2003-.
Lecturer, "The neurobiology of mood disorders;" "The treatment of mood disorders" (in "Biomed 365: The Human Brain and Behavior", for 1st-year Brown medical students), 2005-.
Lecturer, "Mood Disorders: Phenomenology and Overview" (in "The Neurobiology of Disease," Dept. of Neuroscience), 2008.
Leader, "PGY-1-4 Current Issues in Psychiatry Seminar", 2010-.

Butler Hospital

Leader, Attending Consultation Rounds, 2012-.

Selected Publications

  • Tyrka AR, Price LH, Kao H-T, Porton B, Marsella SA, Carpenter LL. Childhood maltreatment and telomere shortening: Preliminary support for an effect of early stress on cellular aging. Biol Psychiatry 67(6):531-534, 2010. (2010)
  • Carpenter LL, Gawuga CE, Tyrka AR, Lee JK, Anderson GM, Price LH. Association between plasma IL-6 response to acute stress and early-life adversity in healthy adults. Neuropsychopharmacology. 35(13):2617-2623, 2010. (2010)
  • Malone DA Jr, Dougherty DD, Rezai AR, Carpenter LL, Friehs GM, Eskandar EN, Rauch SL, Rasmussen SA, Machado AG, Kubu CS, Tyrka AR, Price LH, Stypulkowski PH, Giftakis JE, Rise MT, Malloy PF, Salloway SP, Greenberg BD. Deep brain stimulation of the ventral capsule/ventral striatum for treatment-resistant depression. Biol Psychiatry 65(4):267-275, 2009. (2009)
  • Tyrka AR, Price LH, Gelernter J, Schepker C, Anderson G, Carpenter LL. Interaction of childhood maltreatment with the corticotropin-releasing hormone receptor gene: Effects on hypothalamic-pituitary-adrenal axis reactivity. Biol Psychiatry 66(7):681-685, 2009. (2009)
  • Tyrka AR, Wier LM, Price LH, Ross NS, Anderson GM, Wilkinson CW, Carpenter LL. Childhood parental loss and adult hypothalamic-pituitary-adrenal function. Biol Psychiatry 63(12):1147-1154, 2008. (2008)
  • Carpenter LL, Carvalho JP, Tyrka AR, Wier LM, Mello AF, Mello MF, Anderson GM, Wilkinson CW, Price LH. Decreased adrenocorticotropic hormone and cortisol responses to stress in healthy adults reporting significant childhood maltreatment. Biol Psychiatry 62(10):1080-1087, 2007. (2007)
  • Geracioti TD, Carpenter L, Owens MJ, Baker DG, Ekhator NN, Horn PS, Strawn JR, Sanacora G, Kinkead B, Price LH, Nemeroff CB. Elevated cerebrospinal fluid substance P concentrations in posttraumatic stress disorder and major depression. Am J Psychiatry 163:637-643, 2006. (2006)
  • Carpenter LL, Milosavljevic N, Schecter JM, Tyrka AR, Price LH. Augmentation with open-label atomoxetine for partial or nonresponse to antidepressants. J Clin Psychiatry 66(10):1234-1238, 2005. (2005)
  • Carpenter LL, Tyrka AR, McDougle CJ, Malison RT, Owens MJ, Nemeroff CB, Price LH. Cerebrospinal fluid corticotrophin-releasing factor and perceived early-life stress in depressed patients and healthy control subjects. Neuropsychopharmacology 29(4):777-784, 2004. (2004)
  • Carpenter LL, Anderson GM, Siniscalchi JM, Chappell PB, Price LH. Acute changes in cerebrospinal fluid 5-HIAA following oral paroxetine challenge in healthy humans. Neuropsychopharmacology 28(2):339-347, 2003. (2003)
  • Marek, GJ, Carpenter LL, McDougle CJ, Price LH. Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders. Neuropsychopharmacology 28(2):402-412, 2003. (2003)
  • Cubells JF, Price LH, Meyers BS, Anderson GM, Zabetian CP, Alexopoulos GS, Nelson JC, Sanacora G, Kirwin P, Carpenter L, Malison RT, Gelernter J. Genotype-controlled analysis of plasma dopamine ?–hydroxylase activity in psychotic unipolar depression. Biol Psychiatry 51:358-364, 2002. (2002)
  • Carpenter LL, Heninger GR, McDougle CJ, RT, Tyrka AR, Epperson CN, Price LH. Cerebrospinal fluid interleukin (IL)-6 in obsessive-compulsive disorder and trichotillomania. Psychiatry Res 112:257-262. 2002. (2002)
  • Carpenter LL, Yasmin S, Price LH. A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry 51:183-188, 2002. (2002)
  • Gagne GG Jr, Furman MJ, Carpenter LL, Price LH. The efficacy of continuation ECT and antidepressant drugs compared to long-term antidepressants alone in depressed patients. Am J Psychiatry 157:1960-1965, 2000. (2000)
  • McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive compulsive disorder.Arch Gen Psychiatry 57:794-801, 2000. (2000)
  • Malison RT, Anand A, Pelton GH, Kirwin P, Carpenter L, McDougle CJ, Heninger GR, Price LH. Limited efficacy of ketoconazole in treatment refractory major depression. J Clin Psychopharmacology 19:466-469, 1999. (1999)
  • McDougle CJ, Barr LC, Goodman WK, Price LH. Possible role of neuropeptides in obsessive compulsive disorder. Psychoneuroendocrinology 24:1-24, 1999. (1999)
  • Price LH, Rasmussen SA, Eisen JL. The natural history of obsessive-compulsive disorder [Commentary]. Arch Gen Psychiatry 56:131-132, 1999. (1999)
  • Goddard AW, Woods SW, Money R, Pande AC, Charney DS, Goodman WK, Heninger GR, Price LH. Effects of the CCKB antagonist CI-988 on responses to mCPP in generalized anxiety disorder. Psychiatry Res 85:225-240, 1999. (1999)
  • Price LH, Malison RT, McDougle CJ, Pelton GH, Heninger GR. The neurobiology of tryptophan depletion in depression: Effects of intravenous tryptophan infusion. Biol Psychiatry 43:339-347, 1998. (1998)
  • Malison RT, Price LH, Berman R, van Dyck CJ, Pelton GH, Carpenter L, Sanacora G, Owens MJ, Nemeroff CB, Rajeevan N, Baldwin RM, Seibyl JP, Innis RB, Charney DS. Reduced brain serotonin transporter availability in major depression as measured by [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane and single photon emission computed tomography. Biol Psychiatry 44:1090-1098, 1998. (1998)
  • McDougle CJ, Holmes JP, Carlson DC, Pelton GH, Cohen DJ, Price LH. A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and pervasive developmental disorder not otherwise specified. Arch Gen Psychiatry 55:633-641, 1998. (1998)
  • Barr LC, Goodman WK, Anand A, McDougle CJ, Price LH. Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. Am J Psychiatry 154:1293-1295, 1997. (1997)
  • Price LH, Malison RT, McDougle CJ, McCance-Katz EF, Owen K, Heninger GR. The neurobiology of tryptophan depletion in depression: Effects of m-chlorophenylpiperazine (mCPP). Neuropsychopharmacology 17:342-350, 1997. (1997)
  • Price LH, Cappiello A, Malison RT, McDougle CJ, Pelton GH, Schöllnhammer G, Heninger GR. Effects of antiglucocorticoid treatment on 5-HT1A function in depressed patients and healthy subjects. Neuropsychopharmacology 17:246-257, 1997. (1997)
  • Barr LC, Heninger GR, Goodman W, Charney DS, Price LH. Effects of fluoxetine administration on mood response to tryptophan depletion in healthy subjects. Biol Psychiatry 41:949-954, 1997. (1997)
  • McDougle CJ, Naylor ST, Cohen DJ, Volkmar FR, Heninger GR, Price LH. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry 53:1001-1008, 1996. (1996)
  • McDougle CJ, Naylor ST, Cohen DJ, Aghajanian GK, Heninger GR, Price LH. Effects of tryptophan depletion in drug-free adults with autism. Arch Gen Psychiatry 53:993-1000,1996. (1996)
  • McDougle CJ, Barr LC, Goodman WK, Pelton GH, Aronson SC, Anand A, Price LH. Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder. Am J Psychiatry 152:1812-1814, 1995. (1995)
  • McCance-Katz EF, Price LH, Kosten TR, Jatlow PI. Cocaethylene: Pharmacology, physiology, and behavioral effects in humans. J Pharmacol Exp Ther 274:215-223,1995. (1995)
  • Leckman JF, Goodman WK, Anderson GM, Riddle MA, Chappell PB, McSwiggan-Hardin MT, McDougle CJ, Scahill LD, Ort SI, Pauls DL, Cohen DJ, Price LH. CSF biogenic amines in obsessive compulsive disorder, Tourette's syndrome, and healthy controls. Neuropsychopharmacology 12:73-86, 1995. (1995)
  • Delgado PL, Price LH, Miller HL, Salomon RM, Aghajanian GK, Heninger GR, Charney DS. Serotonin and the neurobiology of depression: Effects of tryptophan depletion in drug-free depressed patients. Arch Gen Psychiatry 51:865-874, 1994. (1994)
  • Anand A, Charney DS, Delgado PL, McDougle CJ, Heninger GR, Price LH. Neuroendocrine and behavioral responses to i.v. m-chlorophenylpiperazine (mCPP) in depressed patients and healthy comparison subjects. Am J Psychiatry 151:1626-1630, 1994. (1994)
  • McDougle CJ, Black JE, Malison RT, Zimmermann RC, Kosten TR, Heninger GR, Price LH. Noradrenergic dysregulation during cocaine abstinence in cocaine addicts:biochemical,behavioral,and cardiovascular correlates.Arch Gen Psychiatry 51:713-19, 1994. (1994)
  • Price LH, Heninger GR. Lithium in the treatment of mood disorders. N Engl J Med 331:591-598, 1994. (1994)
  • Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischman R, Hill C, Heninger GR, Charney DS. The Yale-Brown Obsessive Compulsive Scale (Y-BOCS): I. Development, use, and reliability. Arch Gen Psychiatry 46:1006-1011. 1989. (1989)
  • Price LH, Charney DS, Rubin AL, Heninger GR. Alpha-2 adrenergic receptor function in depression: The cortisol response to yohimbine. Arch Gen Psychiatry 43:849-858, 1986. (1986)